Proceeds from the financing will be used to advance Blueprint Medicines' two lead product candidates through clinical trials in 2015 and fund the continued development of Blueprint Medicines' kinase discovery platform and pipeline.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

45 Sidney St. 200
Cambridge, MA 02139
USA

Phone

(617) 374-7580

Website

www.blueprintmedicines.com

Email Address

[email protected]

Overview

Blueprint Medicines discovers and develops highly selective kinase inhibitors for patients with genomically defined cancers.

Profile

Social Media

Blueprint Medicines Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jeffery Albers

Chief Medical Officer

Anthony Boral

Chief Scientific Officer

Marion Dorsch

Executive Vice President

Christoph Lengauer

VP - Bus. Development

Kate Haviland

VP - Finance

Michael Landsittel

VP - General Counsel

Tracey McCain

VP - Human Resources

Debbie Durso-Bumpus

VP - Operations

Christopher Murray

Browse more venture capital transactions:

Prev: 11/14/2014: iQuartic venture capital transaction
Next: 11/14/2014: Lawn Love venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary